Sector Watch: Healthcare - Sep 10 2018
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $117.94 +0.20 0.17% | XBI: $96.56 +0.15 0.16% | Updated Sep 10, 2018 04:26 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| BLPH Bellerophon Therapeutics $74.0M |
1.28+0.30 7.3 M 5.6x |
30% | ||
| PRQR52WH ProQR Therapeutics $595.3M |
18.65+2.85 2.4 M 5.6x |
18% | ||
| ECYT Endocyte $1.3B |
18.89+1.93 6.7 M 6.0x |
11% | ||
| SRNE Sorrento Therapeutics $642.0M |
5.50+0.55 1.3 M |
11% | ||
| MNKD MannKind $301.4M |
1.97+0.19 11.1 M 1.5x |
11% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| ACOR Acorda Therapeutics $987.7M |
20.80-6.75 3.7 M 9.6x |
-25% | ||
| XBIT52WL XBiotech $99.6M |
2.78-0.80 241.4 K 5.6x |
-22% | ||
| EVFM Evofem BioSciences $105.0M |
4.07-0.63 122.6 K |
-13% | ||
| AST Asterias Biotherapeutics $72.2M |
1.30-0.15 225.1 K |
-10% | ||
| ELGX52WL Endologix $167.7M |
1.98-0.22 1.4 M |
-10% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
Endocyte Announces FDA Acceptance of Radiographic Progression Free Survival (rPFS) as an Alternative Primary Endpoint of the VISION Trial in Addition to Overall Survival (OS) [globenewswire.com]Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido? Pain Medication [globenewswire.com]
Global CAR-T Cell Therapy Market Report 2018 - Market Size, Forecasts, Trials & Trends to 2024 - ResearchAndMarkets.com | Business Wire [businesswire.com]
ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares [globenewswire.com]
Scilex Presents ZTlido? Data on Superior Adhesion over Lidocaine Patch Formulation [prnewswire.com]
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares [globenewswire.com]
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial Nasdaq:PRQR [globenewswire.com]
BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence | Business Wire [businesswire.com]
Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC) [globenewswire.com]
United Therapeutics and MannKind Announce Collaboration for Pulmonary Hypertension Products [globenewswire.com]
Sorrento Therapeutics to Present at FB Riley and HC Wainwright Sept 2018 Healthcare Conferences in NYC (NY) [globenewswire.com]
United Therapeutics And MannKind Announce Collaboration For Pulmonary Hypertension Products [prnewswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
